InnoCare Pharma (HKG:9969, SHA:688428) recorded a net loss attributable to shareholders of 13.6 million yuan for the third quarter of the year, a Monday filing with the Hong Kong Exchange said.
Loss per share stood at 0.01 yuan for the three months ended Sept. 30.
The biopharmaceutical company's operating revenue for the third quarter was 278.0 million yuan, 73.96% higher than a year ago.
For the nine months ended Sept. 30, the company logged an attributable loss of 275.4 million yuan, a loss per share of 0.16 yuan, and 29.85% higher year-on-year operating revenue of 697.7 million.
The company's shares were up over 6% on Monday's close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.